GO:0015019 heparan-alpha-glucosaminide N-acetyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015019 describes the enzymatic activity that transfers an acetyl group from acetyl-CoA onto the terminal alpha-D-glucosamine residue of partially degraded heparan sulfate, a required step in lysosomal heparan sulfate catabolism.
• The activity is encoded by HGSNAT, a lysosomal membrane protein whose deficiency causes mucopolysaccharidosis type IIIC (Sanfilippo syndrome type C).
• HGSNAT is unusual among lysosomal enzymes because it is a transmembrane protein that acetylates its substrate on the luminal side while using cytosolic acetyl-CoA, and it is the only known heparan sulfate acetyltransferase dedicated to degradation.
• Loss of HGSNAT activity leads to accumulation of heparan sulfate oligosaccharides, progressive neurodegeneration, and in some patients non-syndromic retinitis pigmentosa.
• HGSNAT is expressed from a TATA-less promoter with multiple transcription start sites, and its biogenesis and trafficking have been dissected in patient cells and model organisms.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models in cells and animals are powerful tools for studying HGSNAT function and for developing therapies for MPS IIIC.
Description
GO:0015019, heparan-alpha-glucosaminide N-acetyltransferase activity, is a molecular function that catalyzes the acetylation of the terminal alpha-D-glucosamine residue of partially degraded heparan sulfate chains using acetyl-CoA as the acetyl donor. This reaction is essential for the complete lysosomal degradation of heparan sulfate, a highly sulfated glycosaminoglycan involved in cell signaling, extracellular matrix organization, and development. The enzyme responsible for this activity is HGSNAT (heparan-alpha-glucosaminide N-acetyltransferase), a polytopic membrane protein localized to the lysosomal membrane. Because the substrate is generated inside the lysosome while acetyl-CoA is abundant in the cytosol, HGSNAT must bridge two compartments, a unique feature among lysosomal hydrolases. The importance of GO:0015019 is underscored by the fact that biallelic loss-of-function mutations in HGSNAT cause mucopolysaccharidosis type IIIC (MPS IIIC, Sanfilippo syndrome type C), a severe lysosomal storage disorder characterized by progressive neurodegeneration, behavioral abnormalities, and reduced life expectancy. In addition, hypomorphic HGSNAT mutations have been linked to non-syndromic retinitis pigmentosa, highlighting the sensitivity of the retina to even partial loss of this enzymatic activity. The HGSNAT gene is transcribed from a TATA-less promoter with multiple start sites, and its expression is subject to complex regulation. Research on GO:0015019 spans enzymology, structural biology, cell biology, and disease modeling. Recent structural and mechanistic studies have provided insights into how HGSNAT recognizes its substrate and catalyzes acetyl transfer across the lysosomal membrane. Animal models, including Hgsnat-deficient mice and Drosophila melanogaster, have revealed roles for this activity in glial function, testis and epididymis physiology, and immune cell homeostasis. Understanding the molecular details of GO:0015019 is therefore critical for developing targeted therapies for MPS IIIC and related disorders.
heparan-alpha-glucosaminide N-acetyltransferase activity At A Glance
| GO ID | GO:0015019 |
|---|---|
| GO term | heparan-alpha-glucosaminide N-acetyltransferase activity |
| Ontology | molecular_function |
| Synonym | acetyl-CoA:alpha-glucosaminide N-acetyltransferase activity; acetyl-CoA:heparan-alpha-D-glucosaminide N-acetyltransferase activity; heparin-alpha-glucosaminide N-acetyltransferase activity |
| Major function | Acetylation of the terminal alpha-D-glucosamine of heparan sulfate using acetyl-CoA, a required step in lysosomal heparan sulfate degradation |
| Enzyme commission | EC 2.3.1.78 (implied by the reaction) |
| Substrate | alpha-D-glucosaminyl-[heparan sulfate](n) |
| Cofactor | Acetyl-CoA |
| Localization | Lysosomal membrane |
| Associated gene | HGSNAT |
What Is GO:0015019?
GO:0015019, heparan-alpha-glucosaminide N-acetyltransferase activity, is defined as the catalysis of the reaction: alpha-D-glucosaminyl-[heparan sulfate](n) + acetyl-CoA = N-acetyl-alpha-D-glucosaminyl-[heparan sulfate](n) + CoA + H+. In other words, it is the enzyme activity that adds an acetyl group to the free alpha-glucosamine at the non-reducing end of a partially degraded heparan sulfate chain, thereby preparing the substrate for further cleavage by alpha-N-acetylglucosaminidase. This activity is essential for the stepwise breakdown of heparan sulfate inside lysosomes, and its deficiency leads to the accumulation of incompletely degraded heparan sulfate fragments.
Why Is heparan-alpha-glucosaminide N-acetyltransferase activity Important in Cell Biology?
GO:0015019 is a critical enzymatic activity in the lysosomal degradation of heparan sulfate, and its dysfunction directly causes mucopolysaccharidosis type IIIC (Sanfilippo syndrome type C), a devastating neurodegenerative lysosomal storage disorder. Beyond MPS IIIC, partial loss of HGSNAT activity has been associated with non-syndromic retinitis pigmentosa, indicating that the retina is particularly vulnerable to defects in heparan sulfate turnover. The unique membrane topology and catalytic mechanism of HGSNAT make it a paradigm for understanding how lysosomal enzymes handle substrates that are generated in the lumen while using cofactors from the cytosol. Moreover, animal models of HGSNAT deficiency have revealed unexpected roles in glial biology, testicular function, and immune cell homeostasis, broadening the physiological relevance of this activity. Studying GO:0015019 is therefore essential for understanding lysosomal biology, neurodegeneration, and for developing therapies for MPS IIIC and related conditions.
• Deficiency of GO:0015019 causes mucopolysaccharidosis type IIIC (Sanfilippo syndrome type C), a progressive neurodegenerative disorder.
• Hypomorphic mutations in HGSNAT are linked to non-syndromic retinitis pigmentosa, highlighting the importance of this activity in retinal health.
• The reaction is essential for the complete lysosomal degradation of heparan sulfate, a glycosaminoglycan involved in cell signaling and development.
• HGSNAT is a unique lysosomal membrane enzyme that couples cytosolic acetyl-CoA to luminal substrate acetylation, providing a model for membrane-spanning catalysis.
• Animal models, including Hgsnat-deficient mice and Drosophila, have revealed roles for this activity in glia, testis, epididymis, and immune cells.
• The HGSNAT promoter is TATA-less with multiple transcription start sites, suggesting complex transcriptional regulation.
• Structural studies of HGSNAT have provided mechanistic insights into substrate recognition and catalysis, aiding drug design.
• Understanding GO:0015019 is crucial for developing enzyme replacement, gene therapy, or small-molecule chaperone therapies for MPS IIIC.
• The activity is a potential biomarker for lysosomal storage disorders and a target for CRISPR-based disease modeling.
What Happens During heparan-alpha-glucosaminide N-acetyltransferase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs the partially degraded heparan sulfate chain inside the lysosome.
HGSNAT, the enzyme responsible for GO:0015019, is embedded in the lysosomal membrane and recognizes the terminal alpha-D-glucosamine residue of partially degraded heparan sulfate chains that are delivered to the lysosome. The substrate is generated by the action of other lysosomal enzymes, such as heparanase and sulfatases, which trim the heparan sulfate chain but leave a terminal glucosamine that must be acetylated before further cleavage can occur. Structural studies suggest that HGSNAT has a luminal domain that binds the heparan sulfate substrate and a transmembrane region that facilitates acetyl transfer.
Acetyl-CoA utilization and membrane topology
In simple terms: The enzyme uses acetyl-CoA from the cytosol to donate an acetyl group to the sugar inside the lysosome.
Unlike typical lysosomal enzymes that are soluble and use cofactors available in the lysosomal lumen, HGSNAT is a polytopic membrane protein that spans the lysosomal membrane multiple times. Acetyl-CoA, the acetyl donor, is synthesized in the cytosol and cannot freely cross the lysosomal membrane; therefore, HGSNAT must bind acetyl-CoA on the cytosolic side and transfer the acetyl group through a channel or conformational change to the luminal active site. This unique topology allows the enzyme to couple cytosolic acetyl-CoA availability with luminal heparan sulfate acetylation, a mechanism that has been elucidated by biochemical and structural studies.
Catalytic mechanism and acetyl transfer
In simple terms: The enzyme physically moves an acetyl group from one molecule to another, completing the chemical reaction.
The catalytic mechanism of GO:0015019 involves the transfer of an acetyl group from acetyl-CoA to the amino group of the terminal alpha-D-glucosamine, forming N-acetyl-alpha-D-glucosaminyl-[heparan sulfate] and releasing coenzyme A and a proton. Mutational analysis of HGSNAT in patients with MPS IIIC has identified critical residues required for catalysis, and structural studies have provided a framework for understanding how the enzyme positions the substrate and acetyl-CoA for efficient transfer. The reaction is essential for generating a substrate that can be further degraded by alpha-N-acetylglucosaminidase, and its failure leads to the accumulation of heparan sulfate oligosaccharides in lysosomes.
Product release and downstream degradation
In simple terms: After acetylation, the modified sugar is ready for the next enzyme to continue breaking down the chain.
Once the terminal glucosamine is acetylated by GO:0015019, the modified heparan sulfate fragment becomes a substrate for alpha-N-acetylglucosaminidase, which removes the acetylated sugar and allows further degradation of the chain. This sequential action of HGSNAT and other lysosomal enzymes ensures the complete breakdown of heparan sulfate into monosaccharides and sulfate, which can then be recycled or exported from the lysosome. In HGSNAT-deficient cells, this step is blocked, leading to the accumulation of partially degraded heparan sulfate and the characteristic pathology of MPS IIIC.
Regulation of HGSNAT expression and activity
In simple terms: The amount of enzyme produced by the cell is controlled by a complex promoter and multiple transcription start sites.
The HGSNAT gene is transcribed from a TATA-less promoter that contains multiple transcription start sites, which may allow for tissue-specific or developmental regulation of GO:0015019 activity. This promoter architecture is typical of housekeeping genes but also permits fine-tuning of expression in response to cellular demands. Additionally, HGSNAT biogenesis and trafficking to the lysosome are regulated by the secretory pathway, and mutations that affect folding or transport can lead to complete deficiency of the enzyme, as observed in some MPS IIIC patients. Post-translational modifications and interactions with other lysosomal proteins may further modulate its activity, although these aspects require further investigation.
Key Genes Involved in GO:0015019 heparan-alpha-glucosaminide N-acetyltransferase activity
The following genes and proteins are directly or indirectly involved in heparan-alpha-glucosaminide N-acetyltransferase activity (GO:0015019) and its biological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HGSNAT | Encodes the enzyme responsible for GO:0015019; acetylates terminal alpha-glucosamine of heparan sulfate | Mutations cause MPS IIIC and retinitis pigmentosa; target for gene therapy and disease modeling |
| IDS | Iduronate-2-sulfatase; removes sulfate groups from heparan sulfate and dermatan sulfate | Deficiency causes MPS II; upstream of HGSNAT in heparan sulfate degradation |
| SGSH | N-sulfoglucosamine sulfohydrolase; removes sulfate from glucosamine residues | Deficiency causes MPS IIIA; related to heparan sulfate catabolism |
| NAGLU | Alpha-N-acetylglucosaminidase; cleaves acetylated glucosamine residues after HGSNAT action | Deficiency causes MPS IIIB; works downstream of GO:0015019 |
| HGSNAT (mouse Hgsnat) | Murine ortholog of HGSNAT | Hgsnat knockout mice model MPS IIIC and reveal roles in glia and testis |
| Hgsnat (Drosophila) | Drosophila ortholog of HGSNAT | Fruit fly models highlight glial contribution to disease presentation |
| GUSB | Beta-glucuronidase; removes glucuronic acid residues from heparan sulfate | Deficiency causes MPS VII; part of the same degradation pathway |
| GALNS | N-acetylgalactosamine-6-sulfatase; acts on keratan sulfate and chondroitin sulfate | Deficiency causes MPS IVA; not directly in heparan sulfate pathway but related |
| ARSB | Arylsulfatase B; removes sulfate from dermatan sulfate | Deficiency causes MPS VI; overlaps with heparan sulfate metabolism |
| IDUA | Alpha-L-iduronidase; cleaves iduronic acid residues | Deficiency causes MPS I; upstream of HGSNAT in heparan sulfate degradation |
| HYAL1 | Hyaluronidase 1; degrades hyaluronic acid | Not directly involved in heparan sulfate but part of glycosaminoglycan catabolism |
| CTSA | Cathepsin A; protective protein for beta-galactosidase and neuraminidase | Deficiency causes galactosialidosis; may affect lysosomal enzyme stability |
| LAMP1 | Lysosomal-associated membrane protein 1 | Marker of lysosomes; used to study HGSNAT localization |
| LAMP2 | Lysosomal-associated membrane protein 2 | Marker of lysosomes; chaperone-mediated autophagy; may interact with HGSNAT |
| NPC1 | Niemann-Pick C1; cholesterol transport | Mutations cause Niemann-Pick disease type C; lysosomal storage disorder with neurodegeneration |
| TFEB | Transcription factor EB; master regulator of lysosomal biogenesis | May regulate HGSNAT expression and lysosomal function |
| MTOR | Mechanistic target of rapamycin; inhibits autophagy and lysosomal biogenesis | May indirectly affect HGSNAT activity through lysosomal regulation |
| ATF4 | Activating transcription factor 4; integrated stress response | May modulate lysosomal gene expression under stress |
How Is heparan-alpha-glucosaminide N-acetyltransferase activity Regulated?
The expression of HGSNAT, the gene encoding GO:0015019, is regulated at the transcriptional level by a TATA-less promoter with multiple transcription start sites, which may allow for constitutive but adjustable expression across tissues. This promoter architecture is characteristic of housekeeping genes but also permits responses to cellular stress and metabolic demands. The transcription factor TFEB, a master regulator of lysosomal biogenesis, may influence HGSNAT expression as part of the coordinated lysosomal gene network, although direct evidence is still emerging. Additionally, the mTOR signaling pathway, which suppresses autophagy and lysosomal biogenesis, could indirectly affect HGSNAT levels by modulating TFEB activity. At the protein level, HGSNAT biogenesis and trafficking to the lysosome are regulated by the secretory pathway, and mutations that impair folding or transport can lead to complete loss of enzymatic activity, as seen in severe MPS IIIC. Post-translational modifications and interactions with other lysosomal proteins may further fine-tune GO:0015019 activity, but these mechanisms require further investigation.
heparan-alpha-glucosaminide N-acetyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HGSNAT | Mucopolysaccharidosis type IIIC (Sanfilippo syndrome type C) | Hgsnat knockout mouse; patient-derived fibroblasts; CRISPR KO in iPSCs |
| HGSNAT | Non-syndromic retinitis pigmentosa | Retinal organoids; Hgsnat mutant mice; AAV-mediated gene therapy |
| HGSNAT | Testis and epididymis dysfunction; impaired sperm parameters | Hgsnat conditional KO mice; testis cell lines |
| Hgsnat (Drosophila) | Glial dysfunction and neurodegeneration | Drosophila Hgsnat mutants; glial-specific knockdown |
| HGSNAT | Lysosomal storage and heparan sulfate accumulation | CRISPR knock-in of patient mutations in cell lines; biochemical assays |
Mucopolysaccharidosis type IIIC (Sanfilippo syndrome type C)
Biallelic loss-of-function mutations in HGSNAT cause mucopolysaccharidosis type IIIC (MPS IIIC), a lysosomal storage disorder characterized by progressive neurodegeneration, behavioral abnormalities, and early death. The deficiency of GO:0015019 activity leads to the accumulation of partially degraded heparan sulfate in lysosomes, which triggers neuroinflammation, glial activation, and neuronal dysfunction. Mutation spectrum analysis has identified a wide range of pathogenic variants, including missense, nonsense, and splice-site mutations, many of which affect protein folding or catalytic activity. Animal models, such as Hgsnat knockout mice and Drosophila, recapitulate key aspects of the disease and have highlighted the role of glia in disease presentation.
Non-syndromic retinitis pigmentosa
Hypomorphic mutations in HGSNAT that reduce but do not abolish GO:0015019 activity have been identified in patients with non-syndromic retinitis pigmentosa, a degenerative retinal disorder. This finding indicates that the retina is particularly sensitive to defects in heparan sulfate turnover, and that even partial loss of HGSNAT function can lead to photoreceptor degeneration. The mechanism may involve the accumulation of toxic heparan sulfate fragments in retinal cells or impaired lysosomal function in photoreceptors and retinal pigment epithelium. These observations broaden the clinical spectrum of HGSNAT-related diseases beyond classic MPS IIIC.
Roles in testis, epididymis, and immune cells
Inactivation of HGSNAT in mice has been shown to affect the structure and function of epithelial and immune cells in the testis and epididymis, as well as sperm parameters, suggesting that GO:0015019 plays a role in male reproductive physiology. These effects may be due to lysosomal dysfunction in Sertoli cells, epididymal epithelial cells, and resident immune cells, leading to impaired spermatogenesis and sperm maturation. Additionally, Drosophila models of Hgsnat deficiency have implicated glial cells in disease presentation, indicating that non-neuronal cells are important contributors to pathology. These findings highlight the broader physiological importance of heparan sulfate acetylation beyond the central nervous system.
From heparan-alpha-glucosaminide N-acetyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of complete loss of HGSNAT on lysosomal function? | CRISPR knockout of HGSNAT in HeLa, HEK293T, or iPSC-derived neurons |
| How do specific patient mutations affect enzyme activity and trafficking? | Point mutations (e.g., missense variants) introduced by CRISPR in cell lines |
| Can wild-type HGSNAT rescue the disease phenotype? | Knock-in of wild-type HGSNAT or tagged version for localization studies |
| What are the consequences of HGSNAT overexpression? | Overexpression of HGSNAT in cell lines or mouse models via lentiviral or AAV vectors |
| How does HGSNAT deficiency affect glial cells in vivo? | Drosophila Hgsnat mutants with glial-specific drivers |
| What is the role of HGSNAT in testis and epididymis? | Hgsnat knockout mice; conditional KO in reproductive tissues |
How to Study the heparan-alpha-glucosaminide N-acetyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic activity assay | Acetylation of heparan sulfate substrate | Diagnosis of MPS IIIC; functional validation of mutations |
| Western blot | HGSNAT protein expression and processing | Assessing protein stability and trafficking |
| Immunofluorescence | Subcellular localization of HGSNAT | Colocalization with lysosomal markers |
| CRISPR knockout | Loss of HGSNAT function | Modeling MPS IIIC in cell lines |
| CRISPR point mutation | Effect of specific patient variants | Genotype-phenotype correlation |
| CRISPR knock-in | Tagged or corrected HGSNAT | Localization and rescue studies |
| Overexpression | Gain-of-function or rescue | Testing therapeutic potential |
| Animal models | Systemic and neurological phenotypes | Preclinical drug testing |
Enzymatic activity assays
The activity of GO:0015019 can be measured using radiolabeled or fluorescently labeled heparan sulfate substrates and acetyl-CoA, followed by chromatographic separation of the acetylated product. These assays are essential for confirming the functional impact of HGSNAT mutations and for evaluating the efficacy of potential therapies.
Western blotting and immunodetection
Western blotting with anti-HGSNAT antibodies can assess protein expression levels, molecular weight, and processing of the enzyme in cell lysates or tissues. Immunofluorescence microscopy can determine the subcellular localization of HGSNAT and its colocalization with lysosomal markers such as LAMP1.
CRISPR-based genome editing
CRISPR/Cas9 technology enables the generation of knockout, point-mutation, knock-in, and overexpression models to study HGSNAT function in isogenic cell lines. These models are invaluable for dissecting the molecular consequences of specific mutations and for high-throughput screening of therapeutic compounds.
Animal models and behavioral studies
Hgsnat knockout mice and Drosophila mutants are used to study the systemic and neurological effects of GO:0015019 deficiency. Behavioral tests, histopathology, and biochemical analyses of heparan sulfate accumulation provide insights into disease mechanisms and potential treatments.
How CRISPR Can Be Used to Study GO:0015019 heparan-alpha-glucosaminide N-acetyltransferase activity
Knockout
CRISPR/Cas9-mediated knockout of HGSNAT in cell lines or primary cells abolishes GO:0015019 activity, leading to lysosomal accumulation of heparan sulfate and providing a cellular model of MPS IIIC. These knockout models are used to study the downstream consequences of enzyme deficiency, including lysosomal dysfunction, autophagy impairment, and neuroinflammation.
Point Mutation
Introducing specific patient mutations (e.g., missense variants) into the endogenous HGSNAT locus using CRISPR base editing or homology-directed repair allows researchers to study the functional impact of individual variants on enzyme activity, stability, and trafficking. This approach helps establish genotype-phenotype correlations and can reveal which mutations are amenable to chaperone therapy.
Knock-in
Knock-in of wild-type HGSNAT or tagged versions (e.g., GFP, HA) enables precise tracking of the enzyme's localization, trafficking, and interactions within lysosomes. Knock-in models can also be used to correct disease-causing mutations in patient-derived iPSCs for regenerative medicine applications.
Overexpression
Overexpression of HGSNAT in cell lines or animal models via lentiviral or AAV vectors can rescue the deficiency phenotype and is a potential therapeutic strategy for MPS IIIC. Overexpression studies also help determine whether increasing enzyme levels can overcome the block in heparan sulfate degradation and ameliorate disease symptoms.
How EDITGENE Supports heparan-alpha-glucosaminide N-acetyltransferase activity Research
Researchers studying heparan-alpha-glucosaminide N-acetyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in lysosomal storage, neurodegeneration, or retinal degeneration. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell and animal models, enabling functional validation of HGSNAT variants and accelerating therapeutic development for MPS IIIC and related disorders.
Contact EDITGENE today to design your custom CRISPR model for heparan-alpha-glucosaminide N-acetyltransferase activity research.
Frequently Asked Questions About heparan-alpha-glucosaminide N-acetyltransferase activity
What is heparan-alpha-glucosaminide N-acetyltransferase activity?
It is the enzymatic activity (GO:0015019) that transfers an acetyl group from acetyl-CoA to the terminal alpha-D-glucosamine of partially degraded heparan sulfate, a required step in lysosomal heparan sulfate degradation.
What gene encodes heparan-alpha-glucosaminide N-acetyltransferase activity?
The HGSNAT gene encodes the enzyme responsible for this activity.
What diseases are associated with HGSNAT mutations?
Mutations in HGSNAT cause mucopolysaccharidosis type IIIC (Sanfilippo syndrome type C) and have also been linked to non-syndromic retinitis pigmentosa.
What is the reaction catalyzed by GO:0015019?
The reaction is: alpha-D-glucosaminyl-[heparan sulfate](n) + acetyl-CoA = N-acetyl-alpha-D-glucosaminyl-[heparan sulfate](n) + CoA + H+.
Where is HGSNAT located in the cell?
HGSNAT is a lysosomal membrane protein that spans the membrane multiple times, with its active site facing the lysosomal lumen.
How is HGSNAT expression regulated?
HGSNAT is transcribed from a TATA-less promoter with multiple transcription start sites, and its expression may be influenced by lysosomal biogenesis regulators such as TFEB.
What animal models are available for studying HGSNAT deficiency?
Hgsnat knockout mice and Drosophila melanogaster Hgsnat mutants are widely used to study MPS IIIC pathology and glial involvement.
Can CRISPR be used to model MPS IIIC?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models in cell lines and animals are powerful tools for studying HGSNAT function and testing therapies.
What are the symptoms of MPS IIIC?
MPS IIIC is characterized by progressive neurodegeneration, behavioral abnormalities, and lysosomal accumulation of heparan sulfate, with onset typically in early childhood.
How is heparan-alpha-glucosaminide N-acetyltransferase activity measured?
It is typically measured using enzymatic assays with radiolabeled or fluorescent heparan sulfate substrates and acetyl-CoA, followed by product separation.
Conclusion
GO:0015019, heparan-alpha-glucosaminide N-acetyltransferase activity, is a fundamental enzymatic step in lysosomal heparan sulfate degradation, and its deficiency causes the severe neurodegenerative disorder MPS IIIC and contributes to retinitis pigmentosa. The unique membrane topology and catalytic mechanism of HGSNAT have made it a subject of intense structural and biochemical investigation, providing insights into lysosomal biology and membrane-spanning catalysis. Animal models and CRISPR-based cellular models have revealed broader roles for this activity in glia, testis, and immune cells, underscoring its physiological importance beyond the nervous system. Continued research into GO:0015019 will be essential for developing effective therapies for MPS IIIC and related lysosomal storage diseases.
References
- 2. Feldhammer M et al.. 2009. Sanfilippo syndrome type C: mutation spectrum in the heparan sulfate acetyl-CoA: alpha-glucosaminide N-acetyltransferase (HGSNAT) gene.. Hum Mutat 30(6):918-25 PMID: 19479962
- 3. Carvelli L et al.. 2023. Effects of Heparan sulfate acetyl-CoA: Alpha-glucosaminide N-acetyltransferase (HGSNAT) inactivation on the structure and function of epithelial and immune cells of the testis and epididymis and sperm parameters in adult mice.. PLoS One 18(9):e0292157 PMID: 37756356
- 4. Durand S et al.. 2010. Analysis of the biogenesis of heparan sulfate acetyl-CoA:alpha-glucosaminide N-acetyltransferase provides insights into the mechanism underlying its complete deficiency in mucopolysaccharidosis IIIC.. J Biol Chem 285(41):31233-42 PMID: 20650889
- 5. Haer-Wigman L et al.. 2015. Non-syndromic retinitis pigmentosa due to mutations in the mucopolysaccharidosis type IIIC gene, heparan-alpha-glucosaminide N-acetyltransferase (HGSNAT).. Hum Mol Genet 24(13):3742-51 PMID: 25859010
- 6. Hewson L et al.. 2024. Drosophila melanogaster models of MPS IIIC (Hgsnat-deficiency) highlight the role of glia in disease presentation.. J Inherit Metab Dis 47(2):340-354 PMID: 38238109
- 7. Richtrova E et al.. 2016. HGSNAT has a TATA-less promoter with multiple starts of transcription.. Gene 592(1):36-42 PMID: 27452122
- 8. Zhao B et al.. 2024. Structural and mechanistic insights into a lysosomal membrane enzyme HGSNAT involved in Sanfilippo syndrome.. Nat Commun 15(1):5388 PMID: 38918376
